Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

Editorial: Gastrointestinal Hormones.

Paternoster S, Keating D, Falasca M.

Front Endocrinol (Lausanne). 2019 Jul 25;10:498. doi: 10.3389/fendo.2019.00498. eCollection 2019. No abstract available.

2.

Targeting the adipose tissue to fight prostate cancer.

Paternoster S, Falasca M.

Transl Androl Urol. 2019 Jul;8(Suppl 3):S229-S231. doi: 10.21037/tau.2019.01.13. No abstract available.

3.

Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer.

Adamska A, Domenichini A, Capone E, Damiani V, Akkaya BG, Linton KJ, Di Sebastiano P, Chen X, Keeton AB, Ramirez-Alcantara V, Maxuitenko Y, Piazza GA, De Laurenzi V, Sala G, Falasca M.

J Exp Clin Cancer Res. 2019 Aug 5;38(1):312. doi: 10.1186/s13046-019-1308-7.

4.

PLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and -B breast cancer subtypes.

Lattanzio R, Iezzi M, Sala G, Tinari N, Falasca M, Alberti S, Buglioni S, Mottolese M, Perracchio L, Natali PG, Piantelli M.

BMC Cancer. 2019 Jul 30;19(1):747. doi: 10.1186/s12885-019-5949-x.

5.

Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer.

Emmanouilidi A, Fyffe CA, Ferro R, Edling CE, Capone E, Sestito S, Rapposelli S, Lattanzio R, Iacobelli S, Sala G, Maffucci T, Falasca M.

J Exp Clin Cancer Res. 2019 May 14;38(1):191. doi: 10.1186/s13046-019-1191-2.

6.

ABCC3 is a novel target for the treatment of pancreatic cancer.

Adamska A, Ferro R, Lattanzio R, Capone E, Domenichini A, Damiani V, Chiorino G, Akkaya BG, Linton KJ, De Laurenzi V, Sala G, Falasca M.

Adv Biol Regul. 2019 Aug;73. pii: S2212-4926(19)30036-3. doi: 10.1016/j.jbior.2019.04.004. Epub 2019 Apr 24.

PMID:
31053501
7.

Oncogenic and Non-Malignant Pancreatic Exosome Cargo Reveal Distinct Expression of Oncogenic and Prognostic Factors Involved in Tumor Invasion and Metastasis.

Emmanouilidi A, Paladin D, Greening DW, Falasca M.

Proteomics. 2019 Apr;19(8):e1800158. doi: 10.1002/pmic.201800158. Epub 2019 Apr 9.

PMID:
30893511
8.

Pancreatic cancer tumorspheres are cancer stem-like cells with increased chemoresistance and reduced metabolic potential.

Domenichini A, Edmands JS, Adamska A, Begicevic RR, Paternoster S, Falasca M.

Adv Biol Regul. 2019 May;72:63-77. doi: 10.1016/j.jbior.2019.02.001. Epub 2019 Feb 23.

PMID:
30853342
9.

The History of Armand Trousseau and Cancer-Associated Thrombosis.

Metharom P, Falasca M, Berndt MC.

Cancers (Basel). 2019 Jan 31;11(2). pii: E158. doi: 10.3390/cancers11020158.

10.

Metal-based antitumor compounds: beyond cisplatin.

Simpson PV, Desai NM, Casari I, Massi M, Falasca M.

Future Med Chem. 2019 Jan;11(2):119-135. doi: 10.4155/fmc-2018-0248. Epub 2019 Jan 15. Review.

PMID:
30644327
11.

Blood-brain barrier disturbances in diabetes-associated dementia: Therapeutic potential for cannabinoids.

Brook E, Mamo J, Wong R, Al-Salami H, Falasca M, Lam V, Takechi R.

Pharmacol Res. 2019 Mar;141:291-297. doi: 10.1016/j.phrs.2019.01.009. Epub 2019 Jan 4. Review.

PMID:
30616019
12.

Epithelial plasticity is crucial for pancreatic cancer metastatic organotropism.

Adamska A, Falasca M.

Ann Transl Med. 2018 Nov;6(Suppl 1):S53. doi: 10.21037/atm.2018.10.16. No abstract available.

13.

Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1.

Paternoster S, Falasca M.

Front Endocrinol (Lausanne). 2018 Oct 11;9:584. doi: 10.3389/fendo.2018.00584. eCollection 2018. Review.

14.

Properties and prospects for rhenium(i) tricarbonyl N-heterocyclic carbene complexes.

Simpson PV, Falasca M, Massi M.

Chem Commun (Camb). 2018 Nov 1;54(88):12429-12438. doi: 10.1039/c8cc06596a.

PMID:
30302483
15.

ABC transporters as cancer drivers: Potential functions in cancer development.

Domenichini A, Adamska A, Falasca M.

Biochim Biophys Acta Gen Subj. 2019 Jan;1863(1):52-60. doi: 10.1016/j.bbagen.2018.09.019. Epub 2018 Sep 27. Review.

PMID:
30268729
16.

ATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: What is the way forward?

Adamska A, Falasca M.

World J Gastroenterol. 2018 Aug 7;24(29):3222-3238. doi: 10.3748/wjg.v24.i29.3222. Review.

17.

GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine.

Ferro R, Adamska A, Lattanzio R, Mavrommati I, Edling CE, Arifin SA, Fyffe CA, Sala G, Sacchetto L, Chiorino G, De Laurenzi V, Piantelli M, Sansom OJ, Maffucci T, Falasca M.

Oncogene. 2018 Dec;37(49):6368-6382. doi: 10.1038/s41388-018-0390-1. Epub 2018 Jul 30.

PMID:
30061636
18.

Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals.

Abrams SL, Lertpiriyapong K, Yang LV, Martelli AM, Cocco L, Ratti S, Falasca M, Murata RM, Rosalen PL, Lombardi P, Libra M, Candido S, Montalto G, Cervello M, Steelman LS, McCubrey JA.

Adv Biol Regul. 2018 Aug;69:16-34. doi: 10.1016/j.jbior.2018.06.002. Epub 2018 Jun 28.

PMID:
29980405
19.

Oleoyl-lysophosphatidylinositol enhances glucagon-like peptide-1 secretion from enteroendocrine L-cells through GPR119.

Arifin SA, Paternoster S, Carlessi R, Casari I, Ekberg JH, Maffucci T, Newsholme P, Rosenkilde MM, Falasca M.

Biochim Biophys Acta Mol Cell Biol Lipids. 2018 Sep;1863(9):1132-1141. doi: 10.1016/j.bbalip.2018.06.007. Epub 2018 Jun 5.

PMID:
29883799
20.

Molecular and cellular mechanisms of chemoresistance in pancreatic cancer.

Adamska A, Elaskalani O, Emmanouilidi A, Kim M, Abdol Razak NB, Metharom P, Falasca M.

Adv Biol Regul. 2018 May;68:77-87. doi: 10.1016/j.jbior.2017.11.007. Epub 2017 Nov 22. Review.

PMID:
29221990
21.

ABC Transporters in Cancer Stem Cells: Beyond Chemoresistance.

Begicevic RR, Falasca M.

Int J Mol Sci. 2017 Nov 8;18(11). pii: E2362. doi: 10.3390/ijms18112362. Review.

22.

Targeting PDK1 for Chemosensitization of Cancer Cells.

Emmanouilidi A, Falasca M.

Cancers (Basel). 2017 Oct 24;9(10). pii: E140. doi: 10.3390/cancers9100140. Review.

23.

The Role of Platelet-Derived ADP and ATP in Promoting Pancreatic Cancer Cell Survival and Gemcitabine Resistance.

Elaskalani O, Falasca M, Moran N, Berndt MC, Metharom P.

Cancers (Basel). 2017 Oct 24;9(10). pii: E142. doi: 10.3390/cancers9100142.

24.

The role of phospholipase Cγ1 in breast cancer and its clinical significance.

Emmanouilidi A, Lattanzio R, Sala G, Piantelli M, Falasca M.

Future Oncol. 2017 Aug 22. doi: 10.2217/fon-2017-0125. [Epub ahead of print]

PMID:
28829192
25.

Targeting Platelets for the Treatment of Cancer.

Elaskalani O, Berndt MC, Falasca M, Metharom P.

Cancers (Basel). 2017 Jul 22;9(7). pii: E94. doi: 10.3390/cancers9070094. Review.

26.

Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies.

Adamska A, Domenichini A, Falasca M.

Int J Mol Sci. 2017 Jun 22;18(7). pii: E1338. doi: 10.3390/ijms18071338. Review.

27.

mTORC1 activity repression by late endosomal phosphatidylinositol 3,4-bisphosphate.

Marat AL, Wallroth A, Lo WT, Müller R, Norata GD, Falasca M, Schultz C, Haucke V.

Science. 2017 Jun 2;356(6341):968-972. doi: 10.1126/science.aaf8310.

PMID:
28572395
28.

Defining the Anti-Cancer Activity of Tricarbonyl Rhenium Complexes: Induction of G2/M Cell Cycle Arrest and Blockade of Aurora-A Kinase Phosphorylation.

Simpson PV, Casari I, Paternoster S, Skelton BW, Falasca M, Massi M.

Chemistry. 2017 May 11;23(27):6518-6521. doi: 10.1002/chem.201701208. Epub 2017 Apr 12.

PMID:
28337805
29.

Correction: A novel regulatory mechanism links PLCγ1 to PDK1.

Raimondi C, Chikh A, Wheeler AP, Maffucci T, Falasca M.

J Cell Sci. 2017 Mar 1;130(5):1016. doi: 10.1242/jcs.201491. No abstract available.

30.

Epithelial-mesenchymal transition as a therapeutic target for overcoming chemoresistance in pancreatic cancer.

Elaskalani O, Razak NB, Falasca M, Metharom P.

World J Gastrointest Oncol. 2017 Jan 15;9(1):37-41. doi: 10.4251/wjgo.v9.i1.37. Review.

31.

Class II Phosphoinositide 3-Kinases as Novel Drug Targets.

Falasca M, Hamilton JR, Selvadurai M, Sundaram K, Adamska A, Thompson PE.

J Med Chem. 2017 Jan 12;60(1):47-65. doi: 10.1021/acs.jmedchem.6b00963. Epub 2016 Oct 21. Review.

PMID:
27644332
32.

A Small Molecule Inhibitor of PDK1/PLCγ1 Interaction Blocks Breast and Melanoma Cancer Cell Invasion.

Raimondi C, Calleja V, Ferro R, Fantin A, Riley AM, Potter BV, Brennan CH, Maffucci T, Larijani B, Falasca M.

Sci Rep. 2016 May 20;6:26142. doi: 10.1038/srep26142.

33.

Novel roles for class II Phosphoinositide 3-Kinase C2β in signalling pathways involved in prostate cancer cell invasion.

Mavrommati I, Cisse O, Falasca M, Maffucci T.

Sci Rep. 2016 Mar 17;6:23277. doi: 10.1038/srep23277.

34.

Class II phosphoinositide 3-kinase C2β regulates a novel signaling pathway involved in breast cancer progression.

Chikh A, Ferro R, Abbott JJ, Piñeiro R, Buus R, Iezzi M, Ricci F, Bergamaschi D, Ostano P, Chiorino G, Lattanzio R, Broggini M, Piantelli M, Maffucci T, Falasca M.

Oncotarget. 2016 Apr 5;7(14):18325-45. doi: 10.18632/oncotarget.7761.

35.

Pancreatic cancer: Current research and future directions.

Falasca M, Kim M, Casari I.

Biochim Biophys Acta. 2016 Apr;1865(2):123-32. doi: 10.1016/j.bbcan.2016.01.001. Epub 2016 Jan 12. Review.

PMID:
26794394
36.

Lysophosphatidylinositol Signalling and Metabolic Diseases.

Arifin SA, Falasca M.

Metabolites. 2016 Jan 15;6(1). pii: E6. doi: 10.3390/metabo6010006. Review.

37.

Diet and Pancreatic Cancer Prevention.

Casari I, Falasca M.

Cancers (Basel). 2015 Nov 23;7(4):2309-17. doi: 10.3390/cancers7040892. Review.

38.

Role of the lysophosphatidylinositol/GPR55 axis in cancer.

Falasca M, Ferro R.

Adv Biol Regul. 2016 Jan;60:88-93. doi: 10.1016/j.jbior.2015.10.003. Epub 2015 Oct 28. Review.

PMID:
26588872
39.

Design and synthesis of 2-oxindole based multi-targeted inhibitors of PDK1/Akt signaling pathway for the treatment of glioblastoma multiforme.

Sestito S, Nesi G, Daniele S, Martelli A, Digiacomo M, Borghini A, Pietra D, Calderone V, Lapucci A, Falasca M, Parrella P, Notarangelo A, Breschi MC, Macchia M, Martini C, Rapposelli S.

Eur J Med Chem. 2015 Nov 13;105:274-88. doi: 10.1016/j.ejmech.2015.10.020. Epub 2015 Oct 22.

PMID:
26498573
40.

CD31 signals confer immune privilege to the vascular endothelium.

Cheung K, Ma L, Wang G, Coe D, Ferro R, Falasca M, Buckley CD, Mauro C, Marelli-Berg FM.

Proc Natl Acad Sci U S A. 2015 Oct 27;112(43):E5815-24. doi: 10.1073/pnas.1509627112. Epub 2015 Sep 21.

41.

PI3K-C2γ is a Rab5 effector selectively controlling endosomal Akt2 activation downstream of insulin signalling.

Braccini L, Ciraolo E, Campa CC, Perino A, Longo DL, Tibolla G, Pregnolato M, Cao Y, Tassone B, Damilano F, Laffargue M, Calautti E, Falasca M, Norata GD, Backer JM, Hirsch E.

Nat Commun. 2015 Jun 23;6:7400. doi: 10.1038/ncomms8400.

42.

The focal adhesion kinase Pyk2 links Ca2+ signalling to Src family kinase activation and protein tyrosine phosphorylation in thrombin-stimulated platelets.

Canobbio I, Cipolla L, Guidetti GF, Manganaro D, Visconte C, Kim S, Okigaki M, Falasca M, Kunapuli SP, Torti M.

Biochem J. 2015 Jul 15;469(2):199-210. doi: 10.1042/BJ20150048. Epub 2015 May 13.

PMID:
25967238
43.

Activation of phosphatidylinositol 3-kinase β by the platelet collagen receptors integrin α2β1 and GPVI: The role of Pyk2 and c-Cbl.

Manganaro D, Consonni A, Guidetti GF, Canobbio I, Visconte C, Kim S, Okigaki M, Falasca M, Hirsch E, Kunapuli SP, Torti M.

Biochim Biophys Acta. 2015 Aug;1853(8):1879-88. doi: 10.1016/j.bbamcr.2015.05.004. Epub 2015 May 8.

44.

Targeting p110gamma in gastrointestinal cancers: attack on multiple fronts.

Falasca M, Maffucci T.

Front Physiol. 2014 Oct 15;5:391. doi: 10.3389/fphys.2014.00391. eCollection 2014. Review.

45.

New insight into the intracellular roles of class II phosphoinositide 3-kinases.

Maffucci T, Falasca M.

Biochem Soc Trans. 2014 Oct;42(5):1378-82. doi: 10.1042/BST20140140. Review.

PMID:
25233418
46.

Lysophosphatidylinositol: a novel link between ABC transporters and G-protein-coupled receptors.

Ruban EL, Ferro R, Arifin SA, Falasca M.

Biochem Soc Trans. 2014 Oct;42(5):1372-7. doi: 10.1042/BST20140151. Review.

PMID:
25233417
47.

Cancer chemoprevention with nuts.

Falasca M, Casari I, Maffucci T.

J Natl Cancer Inst. 2014 Sep 10;106(9). pii: dju238. doi: 10.1093/jnci/dju238. Print 2014 Sep. Review.

PMID:
25210199
48.

Emerging role of the KRAS-PDK1 axis in pancreatic cancer.

Ferro R, Falasca M.

World J Gastroenterol. 2014 Aug 21;20(31):10752-7. doi: 10.3748/wjg.v20.i31.10752. Review.

49.

Synthesis of Novel 3,5-Disubstituted-2-oxindole Derivatives As Antitumor Agents against Human Nonsmall Cell Lung Cancer.

Nesi G, Sestito S, Mey V, Ricciardi S, Falasca M, Danesi R, Lapucci A, Breschi MC, Fogli S, Rapposelli S.

ACS Med Chem Lett. 2013 Oct 18;4(12):1137-41. doi: 10.1021/ml400162g. eCollection 2013 Dec 12.

50.

PI3K class II α controls spatially restricted endosomal PtdIns3P and Rab11 activation to promote primary cilium function.

Franco I, Gulluni F, Campa CC, Costa C, Margaria JP, Ciraolo E, Martini M, Monteyne D, De Luca E, Germena G, Posor Y, Maffucci T, Marengo S, Haucke V, Falasca M, Perez-Morga D, Boletta A, Merlo GR, Hirsch E.

Dev Cell. 2014 Mar 31;28(6):647-58. doi: 10.1016/j.devcel.2014.01.022.

Supplemental Content

Loading ...
Support Center